Regeneron's Q4 earnings report shows revenue growth, stable EYLEA sales, dividend announcement, and impressive growth for ...

Yancopoulos, Regeneron’s chief scientific officer ... It is administered as a single, weight-based intravenous infusion (50mg atoltivimab, 50mg maftivimab, and 50mg odesivimab per kg).

Regeneron stock has trended bearishly since ... The cost for a supply of 7mL for IV infusion is $11,178. While this is a very rough estimate, sales of a single vial of the drug to 10% of the ...

After Regeneron Chief Scientific Officer George Yancopoulos, M.D., Ph.D., spent more than 25 minutes waxing about the company’s deep pipeline Monday at the J.P. Morgan Healthcare Conference ...

NEW YORK, Jan 13 (Reuters) - Medical data research company Truveta said on Monday that Regeneron Pharmaceuticals (REGN.O), opens new tab, Illumina (ILMN.O), opens new ...

The presentation is scheduled for 2:15 p.m. Pacific Time (5:15 p.m. Eastern Time) and may be accessed from the "Investors & Media" page of Regeneron's website. “The Regeneron name is synonymous ...

DNA sequencing company Illumina and biotech Regeneron have invested in electronic health record data company Truveta to create the largest and most diverse database of genetic information in the ...

Your biospecimen will be sent to the Regeneron Genetics Center for genetic sequencing, then stored for future analysis. With something as sacred as your genetic material in its hands, Truveta and ...

Regeneron collaborates with Truveta and leading American health systems to massively extend its DNA-linked healthcare database to further advance scientific innovation and healthcare delivery ...